Coliprotec F4/F18


porcine post-weaning diarrhoea vaccine (live)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Coliprotec F4/F18. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Coliprotec F4/F18.

For practical information about using Coliprotec F4/F18, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 01/03/2021

Authorisation details

Product details
Coliprotec F4/F18
Agency product number
Active substance
Live non-pathogenic Escherichia coli O141:K94 (F18ac) and O8:K87 (F4ac)
International non-proprietary name (INN) or common name
porcine post-weaning diarrhoea vaccine (live)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Prevtec Microbia GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Geyerspergerstrasse 27
D-80689 Munchen

Product information

25/02/2021 Coliprotec F4/F18 - EMEA/V/C/004225 - IAIN/0007


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals for suidae

  • Live bacterial vaccines

Therapeutic indication

For active immunisation of pigs from 18 days of age against enterotoxigenic F4-positive and F18-positive Escherichia coli in order to reduce the incidence of moderate to severe post-weaning E. coli diarrhoea (PWD) in infected pigs and to reduce the faecal shedding of enterotoxigenic F4-positive and F18-positive E. coli from infected pigs.

Assessment history

Related content

How useful was this page?

Add your rating
2 ratings
4 ratings
9 ratings
2 ratings